硫普罗宁联合多烯磷脂酰胆碱治疗酒精性肝病患者疗效及血清TLR4、MD-2和TGF-β1水平变化

doi:10.3969/j.issn.1672-5069.2021.01.018

Abstract

Abstract: Objective To investigate the short-term efficacy of tiopronin and polyene phosphatidylcholine combination in treatment of patients with alcoholic liver disease (ALD) and its effect on serum toll-like receptor 4(TLR4), myeloid differentiation protein -2(MD-2) and transforming growth factor -β1(TGF-β1) levels. Methods 104 patients with ALD were enrolled in our hospital between January 2018 control group (n=52). The patients in the control group were treated with polyene phosphatidylcholine capsule orally, and those in the observation group were and December 2019, and were randomly divided into observation (n=52) and treated with tiopronin and polyene phosphatidylcholine combination. The treatment in both groups last continuously for 3 months. Serum TLR4, MD-2 and TGF-β1 levels before and after 3 months of treatment were detected by ELISA. Results At the end of three month treatment, serum alanine aminotransferase (ALT) level in the observation group was (34.8±13.9) U/L, much lower than , serum aspartic acid transaminase (AST) level was (43.1±14.2) U/L, significantly lower than , serum total bilirubin (TBIL) level was (15.5±9.7) μmol/L, significantly lower than , and serum gamma-glutamyl transpeptidase (GGT) level was (53.9±14.2) U/L, significantly lower than in the control group; serum total cholesterol (TC) level was (4.1±0.5) mmol/L, much lower than , serum triglyceride (TG) level was (1.3±0.6) mmol/L, significantly lower than , serum high density lipoprotein cholesterol (HDL-C) was (1.2±0.3) mmol/L, significantly higher than , and serum low density lipoprotein cholesterol (LDL-C) level was (3.4±0.9) mmol/L, much lower than in the control; serum TLR4 level was (3.0±0.6) pg/mL, significantly lower than , serum MD-2 level was (415.4±128.5) pg/mL, much lower than , and serum TGF-β1 level was (3.4±1.1) pg/mL, much lower than in the control.Conclusion The combination of tiopronin and polyene phosphatidylcholine in treatment of patients with ALD is efficacious, which might be related to the reduction of serum TLR4, MD-2 and TGF-β1 levels and alleviation of liver function.

Key words: Alcoholic liver disease, Tiopronin, Polyene phosphatidylcholine, Toll-like receptor 4, Myeloid differentiation protein-2, Transforming growth factor-β 1, Therapy

Chen Yanping, Huang Shaoqiang,Deng Xin ,et al. Short-term efficacy of tiopronin and polyene phosphatidylcholine combination in treatment of patients with alcoholic liver disease[J]. Journal of Practical Hepatology, 2021, 24(1): 67-70.

References

[1] Singh S, Osna NA, Kharbanda KK. Treatment options for alcoholic and non- alcoholic fatty liver disease: a review. World J Gastroenterol, 2017, 23(36): 6549-6570.
[2] Stickel F, Datz C, Hampe J, et al. Pathophysiology and management of alcoholic liver disease: update 2016. Gut Liver, 2017, 11(2): 173-188.
[3] 赵慧杰, 肖蕾, 古丽孜拉?拜山, 等. 常用保肝药物对X线照射后人肝细胞HL-7702增殖的影响及对比研究. 中华肝脏病杂志, 2017, 25(8): 612-617.
[4] Mo'men YS, Hussein RM, Kandeil MA. A novel chemoprotective effect of tiopronin against diethylnitrosamine-induced hepatocellular carcinoma in rats: role of ask1/p38 mapk-p53 signalling cascade. Clin Exp Pharmacol Physiol, 2020, 47(2): 322-332.
[5] 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 酒精性肝病防治指南(2018年更新版). 中华肝脏病杂志, 2018, 26(3): 188-194.
[6] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪肝专家委员会.酒精性肝病防治指南(2018年更新版).实用肝脏病杂志,2018,21(2): 170-176.
[7] Lamas-Paz A, Hao F, Nelson LJ, et al. Alcoholic liver disease: utility of animal models. World J Gastroenterol, 2018, 24(45): 5063-5075.
[8] Marroni CA, Fleck AM Jr, Fernandes SA, et al. Liver transplantation and alcoholic liver disease: history, controversies, and considerations. World J Gastroenterol, 2018, 24(26): 2785-2805.
[9] Wang WJ, Xiao P, Xu HQ, et al. Growing burden of alcoholic liver disease in China: a review. World J Gastroenterol, 2019, 25(12): 1445-1456.
[10] Kong LZ, Chandimali N, Han YH, et al. Pathogenesis, early diagnosis, and therapeutic management of alcoholic liver disease. Int J Mol Sci, 2019, 20(11): 2712-2712.
[11] Guo F, Zheng K, Benedé-Ubieto R, et al. The lieber-decarli diet-a flagship model for experimental alcoholic liver disease. Alcohol Clin Exp Res, 2018, 42(10): 1828-1840.
[12] 王海舫, 杨大伟, 贾蓓, 等. 营养支持联合美他多辛治疗酒精性肝病患者肝功能和外周血细胞参数的变化. 实用肝脏病杂志, 2019, 22(3): 381-384.
[13] Li JJ, Zhang P, Fan B, et al. The efficacy of saxagliptin in t2dm patients with non-alcoholic fatty liver disease: preliminary data. Rev Assoc Med Bras (1992), 2019, 65(1): 33-37.
[14] Vincenzi B, Armento G, Spalato Ceruso M, et al. Drug-induced hepatotoxicity in cancer patients - implication for treatment. Expert Opin Drug Saf, 2016, 15(9): 1219-1238.
[15] 孙红菊, 王衍颜, 徐丛聪, 等. 硫普罗宁联合美他多辛治疗酒精性肝病患者疗效初步研究. 实用肝脏病杂志, 2020, 23(1): 54-57.
[16] Hassan NF, Nada SA, Hassan A, et al. Saroglitazar deactivates the hepatic lps/tlr4 signaling pathway and ameliorates adipocyte dysfunction in rats with high-fat emulsion/lps model-induced non- alcoholic steatohepatitis. Inflammation, 2019, 42(3): 1056-1070.
[17] 延喜胜, 李伟, 王剑. 酒精性肝病患者血清细胞因子水平和肠道菌群分布变化研究. 实用肝脏病杂志, 2019, 22(4): 518-521.
[18] Li Y, Xu H, Wu W, et al. Clinical application of angiotensin receptor blockers in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Oncotarget, 2018, 9(35): 24155-24167.
[19] Zhang QZ, Liu YL, Wang YR, et al. Effects of telmisartan on improving leptin resistance and inhibiting hepatic fibrosis in rats with non-alcoholic fatty liver disease. Exp Ther Med, 2017, 14(3): 2689-2694.
[20] Zhong H, Wang L, Gu ZC, et al. Minimal change disease induced by tiopronin: a rare case report and a review of the literature. Ann Transl Med, 2019, 7(16): 398-398.
[21] Li J, Qiu X, Guo W, et al. Prospective analysis of tiopronin in prevention of sorafenib and antiviral therapy inducing liver toxicity in advanced hepatitis B virus-related hepatocellular carcinoma. Med Oncol, 2015, 32(10): 238-238.

Short-term efficacy of tiopronin and polyene phosphatidylcholine combination in treatment of patients with alcoholic liver disease

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhou Xinmin, Ding Xiaopeng. Highlights of conventional supporting therapy for patients with primary liver cancer [J]. Journal of Practical Hepatology, 2021, 24(1): 4-6.
[2]	Liu Qi, Hao Jiqing. Immunotherapy of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2021, 24(1): 7-9.
[3]	Zheng Zhiheng, Li Weiyun, Hui Zhenyu,et al. Serological and virological response topegylated interferon α-2a and entecavir combination in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2021, 24(1): 19-22.
[4]	Lin Jinxiang, Yang Keli. Comparison of response toPEG-IFNα-2a or PEG-IFNα-2b in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2021, 24(1): 27-30.
[5]	Fan Bingdong, Zhang Guohua, Wang Jun. An observation of clinical efficacy of sofosbuvir/vipatavir and ribavirin combination in the treatment of patients with chronic hepatitis C [J]. Journal of Practical Hepatology, 2021, 24(1): 31-34.
[6]	Yang Xiaodong,Jia Ting,Zhang Xiuling, et al. Short-term efficacy of danorevir and peginterferon-α in the treatment of patients with genotype 3 infected chronic hepatitis C [J]. Journal of Practical Hepatology, 2021, 24(1): 35-38.
[7]	Wei Xiuqin, Yan Xiaoxia, Shi Guorong, et al. Short-termefficacy of atorvastatin and tiopronin combination in the treatment of patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2021, 24(1): 47-50.
[8]	Li Zhao, Huang Zansong , Li Fan. Application of fenofibrate and bicyclol combination in treatment of patients with non-alcoholic fatty liver diseases and changes of hepatic PPARγ₂ [J]. Journal of Practical Hepatology, 2021, 24(1): 59-62.
[9]	Chen Jinyu, Guo Xiaoxia, Zhong Xiaoni. Efficacy of bifidobacterium triple viable capsuleand metformin in treatment of patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2021, 24(1): 63-66.
[10]	Cai Yu, Wang Mengchun, Qiu Xinping, et al. Improvement of liver function and subsiding jaundice by compound glycyrrhizin and adenosylmethionine succinate in the treatment of patients with alcoholic hepatitis [J]. Journal of Practical Hepatology, 2021, 24(1): 71-74.
[11]	Wu Chang,Tian Yuan,Liu Hongyan. Short-term efficacy of live clostridium butyricum in assisting tiopronin and metadoxine in treatment of patients with alcoholic liver disease [J]. Journal of Practical Hepatology, 2021, 24(1): 75-78.
[12]	Li Qingling, He Shuguang, Yi Xiaoming, et al. Changes of peripheral blood lymphocyte PD-1 and PD-L1 expression in patients with autoimmune hepatitis receiving tripterygium wilfordii polyglycosides and magnesium iso-glycyrrhizate [J]. Journal of Practical Hepatology, 2021, 24(1): 79-82.
[13]	Zeng Jiao, Guo Guihai. Efficacy and safety of polyethylene glycol and lactulose in the treatment of patients with hepatic encephalopathy:a Meta-analysis [J]. Journal of Practical Hepatology, 2021, 24(1): 99-102.
[14]	Fan Jing, Xu Jing, Yuan Xue. Combination of rifaximin and lactulose improves clinical efficacy and mortality in hepatitis B cirrhotic patients with hepatic encephalopathy [J]. Journal of Practical Hepatology, 2021, 24(1): 103-106.
[15]	Zhang Hua, Sun Baofeng, Liu Shiqi. Combination of oxaliplatin and capecitabine plus bevacizumab in conversion treatment of patients with colon cancer and liver metastasis [J]. Journal of Practical Hepatology, 2021, 24(1): 107-110.